1. J. M. Torres-Flores, A. Reyes-Sandoval, and M. I. Salazar, “Dengue Vaccines: An Update,” BioDrugs, vol. 36, no. 3, pp. 325–336, May 2022, doi: 10.1007/s40259-022-00531-z.
2. Wiyono L, Rocha ICN, Cedeño TDD, Miranda AV, Lucero-Prisno Iii DE. Dengue and COVID-19 infections in the ASEAN region: a concurrent outbreak of viral diseases. Epidemiol Health. 2021;43:e2021070. doi: 10.4178/epih.e2021070.
3. World Health Organization. Dengue in South-East Asia. WHO. 2022 https://www.who.int/southeastasia/health-topics/dengue-and-severe-dengue.
4. Prompetchara E, Ketloy C, Thomas SJ, Ruxrungtham K. Dengue vaccine: Global development update. Asian Pac J Allergy Immunol. 2020 Sep;38(3):178-185. doi: 10.12932/AP-100518-0309.
5. Idris F, Ting DHR, Alonso S. An update on dengue vaccine development, challenges, and future perspectives. Expert Opin Drug Discov. 2021 Jan;16(1):47-58. doi: 10.1080/17460441.2020.1811675.
6. Biswal S, Reynales H, Saez-Llorens X, et al; TIDES Study Group. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. N Engl J Med. 2019 Nov 21;381(21):2009-2019. doi: 10.1056/NEJMoa1903869.
7. Hou J, Ye W, Chen J. Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines. Front Immunol. 2022 Feb 24;13:840104. doi: 10.3389/fimmu.2022.840104.
8. da Silveira LTC, Tura B, Santos M. Systematic review of dengue vaccine efficacy. BMC Infect Dis. 2019 Aug 28;19(1):750. doi: 10.1186/s12879-019-4369-5.
9. Deng SQ, Yang X, Wei Y, Chen JT, Wang XJ, Peng HJ. A Review on Dengue Vaccine Development. Vaccines (Basel). 2020 Feb 2;8(1):63. doi: 10.3390/vaccines8010063.
10. Wilder-Smith A. Dengue vaccine development by the year 2020: challenges and prospects. Curr Opin Virol. 2020 Aug;43:71-78. doi: 10.1016/j.coviro.2020.09.004.
11. Tricou V, Sáez-Llorens X, Yu D, Rivera L, et al. Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial. Lancet. 2020 May 2;395(10234):1434-1443. doi: 10.1016/S0140-6736(20)30556-0.
12. Izmirly AM, Alturki SO, Alturki SO, Connors J, Haddad EK. Challenges in Dengue Vaccines Development: Pre-existing Infections and Cross-Reactivity. Front Immunol. 2020 Jun 16;11:1055. doi: 10.3389/fimmu.2020.01055.
13. Roth C, Cantaert T, Colas C, Prot M, Casadémont I, Levillayer L, Thalmensi J, Langlade-Demoyen P, Gerke C, Bahl K, Ciaramella G, Simon-Loriere E, Sakuntabhai A. A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice. Front Immunol. 2019 Jun 21;10:1424. doi: 10.3389/fimmu.2019.01424.